Retatrutid 30mg

Retatrutid is a novel peptide drug and triple receptor agonist acting on GLP-1, GIP, and glucagon receptors. It aids in weight reduction by regulating appetite, enhancing satiety, and increasing energy expenditure. Retatrutid also improves cardiovascular-metabolic risk markers such as blood pressure, HbA1c, fasting glucose, insulin, cholesterol, and triglycerides. Furthermore, it benefits non-alcoholic fatty liver disease patients by normalizing liver fat. Unlike single or dual agonists, Retatrutid’s triple action mechanism offers more extensive metabolic benefits, making it more effective for weight loss, liver fat reduction, and blood sugar normalization. Retatrutid is a promising new treatment option for obese and type 2 diabetic patients, especially those unresponsive to current treatments.